Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 8 July 2019, 09:31 HKT/SGT
Share:
    

Source: Eisai
Eisai Enters Into Collaboration Research Agreement With University of Dundee on Targeted Protein Degradation Toward Cancer Drug Discovery

TOKYO, July 8, 2019 - (JCN Newswire) - Eisai Co.,Ltd. has entered into a collaboration research agreement with the University of Dundee in Scotland, UK, regarding Proteolysis Targeting Chimeras (PROTACs)(1) toward drug discovery in oncology area. PROTACs consist of two covalently linked protein-binding molecules: one capable of engaging an ubiquitin ligase (E3 ligase) and another that binds to a target protein meant for degradation.

PROTACs work by recruiting an E3 ligase to tag the target protein for ubiquitination for degradation through the intracellular degradation system. It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors. In this collaboration research, Professor Alessio Ciulli, one of the global pioneers in the field of PROTACs research, at the School of Life Sciences, University of Dundee is responsible for directing the research.

The collaboration combines the world-leading expertise and technology of the Professor Alessio Ciulli laboratory in PROTACs research with Eisai's discovery researches and clinical development experiences in oncology area as well as findings of target protein degradation based on our basic researches to aim to create innovative new drugs. Under this agreement, Eisai has the option rights to develop and commercialize the compounds resulted from this collaboration research.

If Eisai exercises the options, an upfront, milestone payments, and royalties on sales will be paid. Eisai positions oncology area as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer. The company will continue to create innovative drugs based on the cutting-edge cancer research and will seek to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

About Proteolysis Targeting Chimeras (PROTACs)

The conventional small molecule inhibitor bind to the active site of targeted enzymes and develops pharmacological actions by inhibiting its function. On the other hand, PROTACs are chimeric compounds with sites for binding targeted protein and for binding ubiquitin ligase and leads to degradation by proteolytic enzyme (proteasome) in cells. Since PROTACs exert their pharmacological effects by the degradation of target proteins, they can not only target proteins that do not have enzyme activity, which is difficult with conventional small molecule inhibitors, but also have pharmacological effects different from inhibitors Is also expected.

About University of Dundee

The University of Dundee is the top ranked university in the UK for biological science, according to the 2014 Research Excellence Framework. Dundee is recognized for the quality of its teaching and research and has a core mission to transform lives across society. More than 15,000 students are enrolled at Dundee, helping make the city Scotland's most student friendly. The university is the central hub for a multi-million-pound biotechnology sector in the east of Scotland, a major contributor to the local economy. For more information, please visit www.dundee.ac.uk.

(1) Gadd M.S. et al. "Structural basis of PROTAC cooperative recognition for selective protein degradation" Nat. Chem.Biol. 13, 514-521 (2017).


About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:
Media Inquiries
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120


July 8, 2019 09:31 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 6, 2020 08:33 HKT/SGT
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan
July 6, 2020 08:05 HKT/SGT
Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan
July 1, 2020 13:02 HKT/SGT
Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID
June 25, 2020 10:47 HKT/SGT
Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea
June 10, 2020 12:49 HKT/SGT
Eisai to Support Counter-Measures Against the Spread of the Novel Coronavirus Infection in Africa
June 4, 2020 10:43 HKT/SGT
Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons
June 2, 2020 10:05 HKT/SGT
Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia
May 29, 2020 14:54 HKT/SGT
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody
May 29, 2020 10:31 HKT/SGT
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials
May 18, 2020 12:33 HKT/SGT
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
More news >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: